Foot care compound possessing antifungal properties

FIELD: medicine.

SUBSTANCE: skin care compound possessing the antifungal properties, alcoholic extract of birch leaves, pine paste, tea tree, fir, lemon and eucalyptus essences, an emulsion base in certain proportions.

EFFECT: compound possesses the pronounced antifungal properties.

4 ex


The invention relates to medicine, in particular to compositions for the care of the skin of the feet with symptoms of mycotic lesions (interdigital mycosis with inflammation, itching and cracks), hyperkeratosis with the formation of corns or cracks in the skin of heels.

Known to use with athlete's foot many synthetic pharmaceuticals. Currently the most popular and the demand for external application use lamisil, mikozoral, mycospor and other synthetic antifungal agents (http://www.rlsnet/ru/news 100393.htm the medicines Register 2013). The pharmaceutical industry is constantly synthesize new antifungal agents as fungal microflora eventually develops resistance to antimycotic agents (mycosamine, mycosporine, bifonazole, nizoral, etc.) by the Lack of means of chemical synthesis is a transient effect, toxicity and the inability of continuous use of them because of the phenomenon of the development of dysbiosis skin. Means of plant origin known "foot Cream (Patent SU 1782588), comprising as active components provitamin concentrate coniferous, coniferous essential oil, aqueous extract of aspen bark, copper chlorophyll derivatives, camphor, menthol.

Known served as the prototype cream p�otography "Molodost", manufactured by LLC "Biolit" Tomsk, which includes birch tar, extract of Siberian fir "Florence", fir oil and emulsion base (Directory of products in the ARGO issue 36). The disadvantage of this tool is primarily unpleasant smell of tar, which prevents the regular use of cosmetics.

The object of the invention is the expansion of compounds of natural origin intended for feet skin care with clinical signs of mycotic lesions, development of the composition of natural origin, allowing its use not only for therapeutic but also prophylactic, for a long time due to the ingredients that possess antifungal properties (for example, treatment of the skin after swimming in pools and other bodies of water, after walking barefoot on the earth or sand in the beach area).

The problem is solved by the following composition of components, wt.%.

Essential oil tea tree 0,2-0,5

Fir essential oil of 0.3-0.8

Eucalyptus essential oil 02-,0,5

Lemon essential oil of 0.3-0.8

The extract of birch leaves 3,0-8,0

Coniferous paste of 0.5-1.0

Emulsion Foundation to 100.0

Give examples of obtaining emulsion base.

Example 1

The emulsion base is prepared according to generally accepted rules by fusing 7,0 � vaseline 0.5 g of beeswax, 5.8 g of lanolin, 1.0 g of dimodan CPU (or emulsion of wax, or sorbifolia, or lipid complex 2, or other emulsifier to the dispersion), 7.0 g of vegetable oil (sunflower, or soy, or corn, or olive, or otherwise), 3.0 g of chicken oil. The ratio of the components of the cream base may vary. Optionally, the emulsion can be introduced additional ingredients to provide a satisfactory quality of consumer cream (antioxidants, preservatives, for example, methylparaben, stabilizers, antiseptics, etc.).

Example 2

Prepare emulsion based fusion 6.0 g perfume oil, 4.8 g of lanolin, 0.5 g of microcrystalline wax, 0.5 g of paraffin wax, 0.5 g of beeswax, the addition of emulsifiers lipid complex - 2.0 g, sorbifolia - and 2.0 g of distilled monoglycerides - 2.0 g, wax emulsion, 4.0 g; vegetable oil - 5.0 g chicken (liposom A) oil and 3.0 g of propyl ester of peroxybenzoate acids - 0.1 g

Give examples of obtaining the proposed composition.

Example 3

Take 24,3 g of emulsion base obtained in example 1, and after cooling it to 45 º C, is slowly added with vigorous stirring in a turbine or other type of stirrer (4-5 thousand rpm) for 25 minutes injected 8.0 g alcohol extra�the birch leaves, 1.0 g of coniferous paste, dissolved 64.1 ml of water. In the resulting emulsion is administered 0.5 g of essential tea tree oil; 0.8 g of silver fir essential oil; 0.8 g of lemon essential oil; 0.5 g of essential oil of eucalyptus at the same rotor speed for 3 minutes until a homogeneous mass of creamy consistency.

The composition prepared cream composition has the following ratio, wt.%:

The extract of birch leaves 8,0

Coniferous paste 1,0

Essential oil tea tree 0.5 to

Fir essential oil 0,8

Lemon essential oil 0,8

Eucalyptus essential oil 0,5

Emulsion cream base to 100.0

Example 4

To 30.4 g obtained in example 2 emulsion base after cooling it to 45ºC added slowly with vigorous stirring in a turbine or other type of stirrer for 25 minutes, 3.0 g of alcoholic extract of birch leaves, 0.5 g of softwood pastas, 65,1 previously dissolved in ml of distilled water. After cooling, the resulting mass to 36 ° C is introduced into the mixture of essential oils: essential oils of tea tree, 0.2 g; essential oils of fir 0.3 g; 0.3 g lemon; essential oils of eucalyptus 0.2 g.

The composition prepared, the composition has the following ratio of components, wt.%:

Ethanolic extract of birch leaves 3

Coniferous pasta 0,5

Essential oil tea tree 0,2

Fir essential oil 03

Lemon essential oil 0,3

Eucalyptus essential oil 0,2

Emulsion Foundation to 100.0

The proposed structure was tested on volunteers in the outpatient setting.

Under supervision there were 20 people with pathological changes of the skin stop: Interdigital athlete's foot and cracking skin on the heels - 11 people.

Cracked skin in the heels of 9 people. Patients used this composition to eliminate itching and healing of defects of the skin between the toes and the soles of 2 times per day, morning and evening.

Healing crack between the toes occurred 3-5 days; elimination of cracks on the skin of the heels was for 10-12 days.

Give specific examples of application of the proposed composition.

Patient K., 72 years of age. Observed within 2 years. Complaints of frequent formation of itchy and painful cracks between the toes. Tried to be treated independently with various ointments (ointment of calendula, dioksidina ointment undecenoate ointments lorinden C), baths with disinfectant solution (weak solution of manganese-acidic potassium, 2% sodium bicarbonate solution), oiled skin of the feet with oil solution of vitamin A (retinol acetate), clortrimazole. All of these remedies were ineffective or had a short lasting effect.

From objective data been paying attention to the cracks between 3 and 4 and 4 and 5 with your fin�mi both feet rough and deep and painful cracked skin of heels, unpleasant odor coming from the socks.

The patient was recommended the use of this tool. She used it after using the toilet legs simple warm water and after draining stop towel applied the cream on the skin of the foot with a thin layer 2 times a day. The effect was rapid and pronounced. Epithelialization cracks occurred after 4 days and cracked heels disappeared for 6 days. Regular application of the cream after washing the feet, at night the skin in the heel smooth. Cracks, and diaper rash between the toes did not recur within 3 months of not even daily use cream.

Example 2

Patient N. aged 56, complained about the thickening of the skin of the plantar surface of the foot, which increases in the summer. On the background of transverse flatfoot she formed excessive cornification of the skin, in the Tarsus of the foot and pain arises as a consequence of callus. Emollient creams, the use of abrasives is ineffective, as 1 to 2 weeks hyperkeratosis is resumed. The patient was recommended to use this tool after the bath acidified with vinegar in warm water (1 tablespoon of 9% solution of vinegar in 1 litre of water). The improvement of the skin foot was observed after 10 days from start of use of the cream.

Example 3. Sick f 65. Suffers from insulin dependent diabetes mellitus for more than 20 years. Diagnosed "Diabetic foot". From objective data draws attention to the atrophy of the skin of the lower leg and the dorsum of the feet. Plantar surface: hyperkeratosis, lamellar desquamation of the skin, interdigital mycosis. Despite the fact that the patient daily washes the feet, use softening creams, skin condition is not improving. After applying mycosoral itching, prompting the patient to abandon synthetic antifungal agents. The patient is recommended to use this at least 2 times a day. The patient applied the cream to the entire foot morning and evening after washing the feet. After two weeks of use the skin of the feet changed: cracking of the skin between your fingers no, skin peeling stopped, hyperkeratosis decreased.

Comparison of the pharmacological activity of the proposed composition with microdonta revealed more rapid and lasting effect of the proposed composition. In the control group of individuals using microdont, in half of the cases the effect was transient and weak. Patients were forced to seek other remedies. At the same time, the study group effect was observed, the overwhelming number of patients.

Thus, the proposed composition allows to expand the range of drugs of natural origin, n�jednoznacnih to combat fungal foot skin. It can be used prophylactically due to the absence of unpleasant odor, characteristic of creams with tar. He has a normalizing effect on the state of the microflora of the skin (clinical data), thereby restores skin structure and barrier function.

Composition for skin care, with anti-fungal properties, including alcoholic extract of birch leaves, pine pasta, essential oils of tea tree, fir, lemon and eucalyptus, based on the emulsion, with the following ratio of components, wt.%:

ethanolic extract of birch leaves3-8
coniferous pasta0,5-1,0
essential oil tea tree0,2-0,5
fir essential oil0,3-0,8
lemon essential oil0,3-0,8
eucalyptus essential oil0,2-0,5
emulsion Foundation100.0


Same patents:

FIELD: medicine.

SUBSTANCE: therapeutic agent contains recombinant interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, fluconazole and/or voriconazole, and a pharmaceutically acceptable base in the following proportions, g per 1 ml of the mixture: recombinant interferon, international units 100-10,000,000; metronidazole 0.00001-0.5; fluconazole and/or voriconazole 0.00001-0.5; pharmaceutically acceptable base - the rest. Besides, the therapeutic agent contains boric acid in an amount of 0.00001-0.5 g and hypromellose in an amount of 0.00001-0.5 g. As a pharmaceutically acceptable base, it contains macrogol 400 or macrogol 1500, or macrogol 4000.

EFFECT: higher efficacy of the compound.

2 cl, 5 ex

FIELD: biotechnology.

SUBSTANCE: strain Trametes versicolor is proposed, used for production of antifungal agents against fungi of the genus Penicillium. The strain is deposited in the RCIM under the number F-1024.

EFFECT: strain has high chitinase and fungicidal activity.

4 dwg, 1 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: method of producing a carbon sorbent with antibacterial and antimycotic properties includes impregnating granules of a carbon hemosorbent with 10-50% aqueous solution of glycolic acid for 7-9 hours at room temperature. The ratio of the hemosorbent to the modifier solution of glycolic acid is 1:1. Further, drying is carried out for an hour at 100-110°C. Polycondensation of glycolic acid on the carbon hemosorbent is carried out in two steps: at 185-205°C for 1 hour, at 215-235°C for not less than 5 hours, on a sand bath. The disclosed modified carbon sorbent with antibacterial and antimycotic properties is granules with a round shape, contains not less than 5% polyglycolide, characterised by a specific adsorption surface area of less than 250 m2/g and total pore volume of less than 0.50 cm3/g.

EFFECT: improved properties of the sorbent.

2 cl, 2 tbl, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to antifungal compounds based on 3,5,8-trioxabicyclo[5,1,0]octane derivatives, obtained by trans-opening of its epoxide cycle, namely 6-(arylthio)-1,3-dioxepan-5-ols in racemic and enantiopure form of the general formula Ia and Ib , where at R1=F, R2=H, R3=H; at R1=Br, R2=H, R3=H; at R1=H, R2=Br, R3=H; at R1=H, R2=H, R3=Br.

EFFECT: compounds of formula Ia and Ib possess low toxicity and high antifungal activity with respect to fungi Candida albicans, Aspergillus fumigatus, Epidermophyton floccosum, Mucor pusilos, Saccharomyces cerevisiae and can be applied in medicine and veterinary.

2 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: as an active substance, the composition contains butoconazol, a base that is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and also a gel-forming polymer. Hydroxypropylstarch phosphate is preferentially used as the gel-forming polymer. A method for preparing the declared composition consists in the fact that a mixture of butoconazol with a portion of the hydrophilic ingredient, the hydrophobic ingredient and emulsifier is added with a dispersion of the gel-forming polymer in the rest of the hydrophilic ingredient; the produced mixture is agitated homogenously with a preserving agent added where it might be necessary.

EFFECT: new pharmaceutical composition is characterised by a high level of antifungal activity, stability both at a storage temperature, and at a use temperature, and good pack extrusion.

14 cl, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention represents an antifungal preparation in suppositories for children containing recombinant human interferon 2α and fluconazole, wherein lysozyme, Licopid and dimephosphone are additionally introduced.

EFFECT: preparation possesses the high clinical effectiveness in the fungal diseases in children that leads to reducing the length of treatment and prolonging the intercurrent period.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the field of medicine, namely to pharmacology, and describes a composition, containing fulvic acid or its salt and an antifungal compound, selected from fluconazole and amphotericin B. In accordance with the first version of the implementation the composition contains about 10 ml/kg of a solution of from about 0.25% to about 1% (wt/vol) fulvic acid or its salt and of about 10 mg/kg fluconazole. In accordance with the second version of the implementation the composition contains 0.25% (wt/vol) of the solution of fulvic acid or its salt and from about 0.06 mg/l to about 0.5 mg/l of amphotericin B.

EFFECT: invention can be used in a method of treating a fungal infection of the human or animal body, the method includes the introduction to an object, requiring it, of a therapeutically effective quantity of the composition.

11 cl, 1 dwg, 10 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to veterinary science and is applicable for treating the animals suffering from bacteriosis and yeast mycosis. A declared preparation contains oxytetracycline hydrochloride, sulphadimine, ampicillin sodium, nistatine, a solvent and the active substance conduit dimethyl sulphoxide, the quick-relief anaesthetic lidocaine in the following proportions, wt %: ampicillin sodium 4.0-8.0, oxytetracycline hydrochloride 2.0-4.0, nistatine 1.0-2.0, sulphadimine 2.0-4.0, novocaine 0.25-0.5, lidocaine 0.25-0.5, dimethyl sulphoxide 10.0-20.0, 1,2-propylene glycol - the rest. A method of treating the animals consists in administering the declared preparation in a dose of 0.1-0.2 cm3 per 1 kg of body weight.

EFFECT: using the declared group of inventions is high-efficiency for treating the animals suffering from bacteriosis and yeast mycosis and enables improving livestock farms with an unfavourable incidence of bacteriosis and yeast mycosis.

5 cl, 9 ex

FIELD: chemistry.

SUBSTANCE: preparation can be applied for elimination of fungi and in treatment of diseases, caused by fungi, as well as for the prevention of damage by fungi to different materials and agricultural products. The fungicidal preparation represents an associate of 5-[3,5-dichloro-2-hydroxybenzylidine)amino]-4-hydroxy-1H-pyrimidine-2-one with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and corresponds to the following formula: . Compounds were obtained in the crystalline form, and their structure is proved by spectra of proton magnetic resonance in dimethylsulphoxide.

EFFECT: preparation has a wide spectrum of action and high solubility, which increases efficiency of its application in the form of solutions.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to compositions and polymeric materials for biomedical use, comprising silver nanoparticles (0.0005-0.02 wt %) stabilised by amphiphilic copolymers of maleic acid (0.0008-0.05 wt %), low molecular weight organic amines (0.0002-0.04 wt %) and water. In addition, the said composition may additionally comprise the polymeric structure-forming agent.

EFFECT: introduction to the composition of the polymer structure-forming agent enables to obtain the macroporous structured hydrogel materials having prolonged bactericidal and antifungal action.

3 cl, 2 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel pyridine derivatives of the general formula

and to their pharmaceutically acceptable salts, where R1 stands for (C1-6) alkyloxy, CN or halogen, R2 stands for a hydrogen atom, R3 stands for a hydrogen atom or (C1-6) alkyl, R4, R5, R6, R7 are similar or different and stand for a hydrogen atom or halogen. The invention also relates to the cosmetic application of the formula (I) compound.

EFFECT: novel pyridine derivatives, useful in the treatment of diseases associated with a receptor of androgens, are obtained.

9 cl, 1 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of general formula I, their pharmaceutically acceptable salts or N-oxides. In general formula , R1 represents C1-6alkoxy, such as methoxy or hydroxy; R2 represents C3-5cycloalkyl, which is optionally substituted by one substitute specified in R4, wherein R4 means C1-4alkyl, which is optionally substituted by hydroxy, C1-4alkoxy, group -OC(O)NR5R6, wherein each of R5 and R6 independently represents a hydrogen atom, C1-4alkyl, C3-6cycloalkyl, or R5 and R6 together with a nitrogen atom where they are attached to, form pyrrolidinyl, group -NHC(O)R7, wherein R7 means C1-4alkyl, C3-5cycloalkyloxy or pyrrolidinyl, or benzyloxygroup; -C(O)NR7R8, wherein each of R7 and R8 independently represents a hydrogen atom or C1-4alkyl, which in turn can be substituted by hydroxy, oxo, cyano, group -SO2C1-4alkyl, group -SO2NR11R12, wherein each of R11 and R12 independently represents a hydrogen atom or C1-4alkyl, group -NHSO2C1-4alkyl, group -NHC(O)C1-4alkyl, group -C(O)NR7R8, wherein R7 and R8 together with a nitrogen atom, where they are attached to, form morpholinyl, -OC(O)C2-6alkenyl, phenyl, pyridinyl or C3-6cycloalkyl, or R7 and R8 together with a nitrogen atom where they are attached to, form 5-6-merous cycle specified in morpholinyl, piperidinyl, piperazinyl substituted by C1-4alkyl, or pyrrolidinyl; -COOR7, wherein R7 means a hydrogen atom or C1-4alkyl; A represents phenyl optionally one or two-substituted by cyano, halogen, hydroxyl, C1-4alkyl, halogenC1-4alkyl, C1-4alkoxy, halogenC1-4alkoxy, C1-4alkoxyC1-4alkoxy, -SO2C1-4alkyl, group -C(O)OR3, wherein R3 means a hydrogen atom or C1-4alkyl, -C(O)R3, wherein R3 means C1-4alkyl, amino, C1-4alkylamino or diC1-4alkylamino, -NR5R6, wherein R5 and R6 independently mean hydrogen, -C(O)C1-4alkyl or -SO2C1-4alkyl, -C1-4alkylNR5R6, wherein R5 and R6 independently mean hydrogen or -SO2C1-4alkyl, or -C1-4alkylC(O)OR3, wherein R3 means C1-4alkyl, -SO2NR11R12, wherein R11 and R12 independently mean a hydrogen atom or C1-4alkyl substituted by hydroxy, or R11 and R12 together with a nitrogen atom where they are attached to, form morpholinyl; pyrrolidinyl optionally substituted by cyano; pyrimidinyl; thiophenyl optionally substituted by C1-4acyl; piperidinyl; 4,5-dihydro-2H-pyridazinone substituted by C1-4alkyl; dihydrobenzofuranone; oxoindanyl; or dihydro-oxoindolyl; X and Y represent either C and N, or N and C, respectively.

EFFECT: there are prepared new compounds, which possess the inhibitory activity on PDE4.

6 cl, 53 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to using a preparation containing the strain Bifidobacterium breve and a mixture of two soluble ingredients A and B for preparing a composition for prevention and treatment of diaper skin rash in the children. The content of the carbon ingredient A in the preparation makes 5-95 wt % of total content of the ingredients A and B. The ingredients A and B differ by an average number of monosaccharide carbohydrate links with an average chain length of the ingredient A is at least 5 monosaccharide links less than the average chain length of the ingredient B, and a structure of the monosaccharide carbohydrate links.

EFFECT: invention provides reducing allergic reactions in skin rash in the children.

9 cl, 2 dwg, 7 tbl, 29 ex

FIELD: medicine.

SUBSTANCE: skin regeneration is stimulated by using a synthetic analogue of indolicidine, a natural antimicrobial peptide having formula H-Lys-Lys-Pro-Trp-Lys-Trp-Pro-Lys-Lys-Pro-Trp-Arg-Arg-NH2.

EFFECT: accelerating reparative skin regeneration following a burn injury.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to a composition for treating dermatologic diseases, preferentially skin itching. The composition causes antiallergic action and is used in treating allergic reactions (rash, urticaria), insect bites, ultraviolet erythema and skin burns. The pharmaceutical composition contains azelastine hydrochloride and benzocaine as active substances, and a hydrophobic ingredient, a hydrophilic ingredient, an emulsifying agent and a pH corrective agent as additive agents. As the pH corrective agent, the composition contains preferentially succinic acid. The pharmaceutical composition is presented as a soft dosage form, preferentially in the form of a cream.

EFFECT: composition according to the invention is characterised by high pharmacologic activity, good package extrusion, and storage-stability.

9 cl, 1 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: composition contains dexpanthenol, 20% chlorhexidine bigluconate, propylene glycol, a mixture of dimethicone, isopropyl myristate and Vaselin oil, a mixture of macrogol 20 cetostearyl ester and cetostearyl alcohol, glycoceramides, DL-pantolactone, a propellant and a solvent.

EFFECT: composition is safe and effective; it complies with the requirements of current officinal requirements for pharmaceutical foams, regulatory requirements for microbiological purity and has a 2-year shelf life.

5 cl, 4 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: group of inventions relates to cosmetic depigmenting composition and to its application for skin depigmentation. As depigmenting agent claimed is delta-tocopheryl carbohydrate, preferably delta-tocopheryl-glucopyranoside.

EFFECT: high depigmenting activity of compound.

13 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: common therapy is conducted in the patient according to standard regimen. Additionally, from the first therapeutic day, Ananferon for kids and Virefon, suppositories are prescribed. Anaferon for kids is administered subglosally without regard to food in a dose of 1 tablet once a day for 2 months. Viferon, rectal suppositories are used 2 times a day every 12 hours for 30 days according to the schedule: for the first 10 days, 1 suppository of 1,000,000 international units, for the following 10 days, 1 suppository of 500,000 international units and then 1 suppository of 150,000 international units.

EFFECT: using the given method enables normalising the immune status values, prolonging the remission of clinical manifestations of atopic dermatitis in the children with secondary immunodeficiency syndrome.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which can be used for treating diseases mediated by an androgen receptor. In formula (I), R1 means (C2-6)alkyl, (C1-6)alkyloxy, -S(O)m-(C1-6)alkyl, (C1-6)fluoroalkyl, CN or halogen, R2 and R3 are identical or different and mean a hydrogen atom or (C1-9)alkyl, R4, R5, R6, R7 are identical or different and mean a hydrogen or halogen, X means CH or N, Y means either a nitrogen atom, or a carbon atom substituted by (C1-6)alkyl, (C1-6)alkyloxy, (C1-6)fluoroalkyl, a hydrogen atom or halogen; m is equal to 0, 1 or 2.

EFFECT: invention refers to using the compounds for preparing a therapeutic agent for preventing and/or treating hirsutism, androgenetic alopecia, hypertrichosis, atopic dermatitis, disordered sebaceous gland, such as hyperseborrhea, acne, greasy skin or seborrheic dermatitis.

8 cl, 2 tbl, 26 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula


where X=S, SO or SO2, and one of radicals R1 and R2 is a hydrogen atom and the other has a value given in the claim, which are used for depigmentation of the skin and/or hair and/or body hair and for skin disinfection, to cosmetic application of the disclosed compounds, and to compounds of formula (I), wherein R1 and R2 can also be a hydrogen atom at the same time. The invention also relates to a cosmetic composition and a pharmaceutical composition based on the disclosed compounds and to methods of producing said compounds.

EFFECT: improved properties.

19 cl, 2 tbl, 30 ex

FIELD: medicine.

SUBSTANCE: application of a mixture of triterpenoids, containing β-amyrin 27.48 wt %, α-amyrin 27.52 wt %, moretenol 25.52 wt %, lupeol 19.48 wt % or butyro-lignans - arctiin or arctigenin, separated from Alfredia cemua (L.) Cass., as a medication, possessing a cerebroprotective action. The said mixture of triterpenoids or butyro-lignans - arctiin or arctigenin, separated from Alfredia cemua (L.) Cass., possess the expressed cerebroprotective action.

EFFECT: increased efficiency of the medication application.

1 tbl, 2 ex